KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

Summary

This KOL Insight briefing focuses on KOLs views of recent & upcoming data for key HBV pipeline agents.

Questions topics -

• Further Phase I data required for Roche’s capsid inhibitor RO7049389


• Replicor’s US trial plans and transition from IV to subcutaneous REP 2139


• Efficacy of Spring Bank’s inarigivir at 100mg in the Phase II ACHIEVE trial


• Expected role for inarigivir in HBV


• Efficacy of Arbutus’s Q2W IV ARB-1467


• ARB-1467, TDF + Peg-IFN trial design, potential for functional cure, & regimen acceptability


• Future development of Arbutus’s next-generation RNAi therapeutic AB-729For internal use only

Key Highlights

• Divided views on most relevant Phase I data required to differentiate RO7049389 from JNJ-6379 & ABI-H0731, with most concluding that Phase I data is insufficien


• KOLs agree Replicor is making positive steps towards REP 2139’s development, but similar efficacy & safety must be demonstrated in the US trials and for the SC formulation


• Disagreement between US and EU KOLs over the improvement in efficacy of inarigivir at the 100mg dose.

Scope

• The insight briefing is based on Sociable Pharma’s analysis of primary research with our HBV key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -

• 5 Europe-based & 5 N. America-based


• Interviews performed during Sept 2018

KOL data is analyzed to produce -

• Charts summarizing KOL opinions


• Chart call-outs of key information & details


• KOL quotes


• Summary of KOL reporting trends


• Insight from Sociable Pharma's analysts

Reasons to Buy

• Combines Qualitative & semi-quantitative insight from key opinion leaders on "recent & upcoming data for key HBV pipeline agents"


• Includes insight & recommendations from our disease-specific healthcare analysts


• Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of HBV


• Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.